Latest research on Avastin

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Latest findings

Recently, Genentech developed a humanized monoclonal antibody to VEGF (Bevacizumab, Avastin); it is now under Phase III clinical trails for the treatment of colorectal, breast, and non-small cell of the lung cancer [2]. [source, 2004]
Notably, soluble antagonists of the VEGF receptors, specific TYROSINE kinase inhibitors (Su5416) and monoclonal antibodies against VEGF (bevacizumab, Avastin) have been developed to target the tumor endothelium specifically. [source, 2003]
Recent reports, however, indicate that although Avastin showed initial promise in combating breast tumor angiogenesis, follow-up studies showed that the long-term prognosis in treated patients was not improved. [source, 2003]